Form 4: Elicio Therapeutics Director Acquires Stock Options

Karen Wilson, a director at Elicio Therapeutics, acquired 4,100 stock options on November 21, 2024.

Summary

• Karen Wilson, a director of Elicio Therapeutics, acquired 4,100 stock options on November 21, 2024.
• The options have an exercise price of $5.12 per share.
• The options will vest on the earlier of November 21, 2025, or the next annual meeting of the company's stockholders after the grant date, provided Ms. Wilson continues to provide services to the company.
• The options expire on November 21, 2034.

Sentiment

Score: 7

Explanation: The document reflects a standard insider transaction, which is generally neutral to positive as it aligns director interests with shareholders. The sentiment is slightly positive due to the director's increased stake in the company.

Positives

• The acquisition of stock options by a director may indicate confidence in the company's future performance.

Future Outlook

The stock options will vest based on continued service and a future date or event.

Industry Context

This is a standard transaction for a director of a publicly traded company, often used as part of compensation packages.

Comparison to Industry Standards

• Stock option grants to directors are a common practice in the biotechnology industry, aligning their interests with those of shareholders.
• The vesting schedule of one year or the next annual meeting is typical for such grants.
• The 10-year expiration period is also standard for stock options.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of shareholders, potentially encouraging actions that increase shareholder value.

Key Dates

Keywords

stock options, director, Elicio Therapeutics, ELTX, insider trading, equity